Immune-checkpoint inhibitors represent one of the most important therapy advancements in modern oncology. They are currently used for treatment of multiple malignant diseases especially at advanced, metastatic stages which were poorly therapeutically accessible in the past. A challenging aspect of these immunotherapies is that they may show atypical therapy response patterns such as pseudoprogression and demonstrate a different imaging spectrum of adverse reactions, both of which are crucial for radiologists to understand.
In this review article, Thorsten Persigehl, Simon Lennartz & Lawrence H. Schwartz provide guidance for response assessment of oncologic patients under immunotherapy based on iRECIST criteria.